Pharmaceuticals
MPM Capital forms VC fund with Japan's Astellas Pharma
MPM Capital, a US venture firm focused on early-stage life science companies, has launched a new investment vehicle in partnership with Japanese pharmaceutical company Astellas Pharma.
Australia's Brandon Capital expands into New Zealand
Australian life sciences-focused VC firm Brandon Capital has expanded the mandate of its third Medical Research Commercialization Fund (MRCF) to include New Zealand.
Diamedica gets $4m for China push
Hermed Capital Healthcare Fund, a PE vehicle managed by Shanghai Fosun Pharmaceutical Group and Korea’s SK Group, has committed $4 million to a China expansion drive by US-based Diamedica.
Creador invests $18m in India's Corona Remedies
Creador has committed INR1.2 billion ($17.6 million) to India-based pharmaceutical developer Corona Remedies.
Singapore's Aslan Pharma raises $23m pre-IPO round
Singapore-based biotech company Aslan Pharmaceuticals has raised $23 million in a pre-IPO financing round that attracted participation from a range of new investors, including a number of Taiwanese groups.
Quadria buys into India's Concord Biotech
Quadria Capital has led a consortium including US-based investment firms Rising Tide and Neuberger Berman to take a stake in India’s Concord Biotech.
Mandala buys India's EFRAC for $10m
Mandala Capital, a South-Asia focused PE firm that invests in the agricultural sector, has paid $10 million for a 51% stake in Indian testing laboratory EFRAC.
Shenzhen Hepalink commits $60m to TPG biotech fund
Chinese drug maker Shenzhen Hepalink Pharmaceutical has agreed to commit $60 million to TPG Capital’s latest biotech fund.
IFC to anchor $200m round for India's Glenmark
The International Finance Corporation (IFC), the investment arm of the World Bank, will anchor a planned $200 million funding round for India's Glenmark Pharmaceuticals, committing up to $75 million.
Fosun Pharma makes offer for India's KKR-backed Gland
Hong Kong-listed drug maker Fosun Pharmaceutical has made a non-binding proposal to acquire Gland Pharma, an Indian pharmaceutical developer backed by KKR.
Harvest leads $50m round for China’s Hua Medicine
Harvest Fund Management has led a $50 million Series C round – which was more than 3x oversubscribed – for China-based clinical-stage diabetes treatment developer Hua Medicine.
China’s cancer drug developer Ascentage secures $15m
Ascentage Pharma Group, a Shanghai-based cancer drug developer, has raised a RMB95 million ($15 million) Series A round of funding led by Oriza Seed and YuanMing Capital.
Cathay Capital invests in European pharma firm Cenexi
Cathay Capital Private Equity has invested an undisclosed sum in Cenexi Group, a French pharmaceutical contract manufacturer.
Singapore's Temasek, CVC agree $2b deal for US generic drug firm
Singapore's Temasek Holdings is a member of a CVC Capital Partners-led consortium that has agreed to buy a controlling stake in US-based generic drug manufacturer Alvogen. The deal is said to value the company at $2 billion.
India's ChrysCapital exits stake in Mankind Pharma
ChrysCapital Partners has sold its 11% stake in India-based Mankind Pharma to investment firm Capital International for just over $200 million, valuing the company at about $2.2 billion.
China’s BeiGene raises $97m from PE investors
BeiGene, a Chinese company that develops drugs to combat cancer, has raised RMB600 million ($97 million) in a funding round led by existing investors Hillhouse Capital and an undisclosed US-based life sciences-focused public investment fund.
Brandon raises $154m for Australia life sciences fund
Australian life sciences-focused VC firm Brandon Capital has reached a A$200 million ($154 million) final close on its latest vehicle - the Medical Research Commercialisation Fund 3 (MRCF 3).
Temasek invests $151m in India's Glenmark Pharma
Singapore state-backed investment group Temasek Holdings has invested INR9.45 billion ($151 million) in India's Glenmark Pharma via a preferential allotment of shares.
Vivo closes latest Sino-US healthcare fund at $750m
US-based Vivo Capital has closed its eighth fund at $750 million. It will invest in healthcare companies in the US and China.
China’s online drugstore 7LK raises $48m from VCs
Chinese online drugstore 7LK.com has raised RMB300 million ($48 million) in a Series A round of funding from Govtor Capital, Grand Yangtze Capital and TusPark Ventures.
Japan's Mitsui Global backs clinical SaaS start-up
Japan’s Mitsui Global Investment and Dolby Family Ventures have together invested $12 million in cloud-based, clinical study software start-up goBalto.
China's BVCF provides $8m round for US biotech firm
China-focused biotech investor BVCF has led an $8 million Series A round of funding for DiaCarta, a US-based firm that develops test kits for detecting cancer.
Qiming leads $10m round for China biopharma player
Qiming Venture Partners has led a $10 million Series A round of funding for CANbridge Life Science, a Beijing-based biopharmaceutical firm.
CVC to raise $80m via Jintian Pharma share sale
CVC Capital Partners will raise HK$620 million ($80 million) through a block trade of shares in Jintian Pharmaceutical Group, a Chinese pharmaceutical retailer and distributor.